This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute promyelocytic leukemia (APL)	Lysine-specific histone demethylase 1 (KDM1A; LSD1); KDM1B (LSD2)	<i>In vitro</i> studies suggest that tranylcypromine-derived LSD1 and LSD2 inhibitors could help treat APL. Synthesis and <i>in vitro</i> testing of 40 tranylcypromine analogs identified a low-micromolar inhibitor of LSD1 and LSD2. In a human APL cell line and primary mouse APL cell culture, the inhibitor plus retinoic acid, a standard APL therapy, produced better reductions in cell growth and proliferation than did retinoic acid alone. Ongoing studies include lead optimization and testing lead compounds in animal models of leukemia and solid tumors.	Patented; available for licensing Contact: Daniela Bellomo, director of technology transfer, European Institute of Oncology, Milan, Italy email: daniela.bellomo@ifom-ieo-campus.it	Binda, C. <i>et al. J. Am. Chem. Soc.</i> ; published online April 23, 2010; doi:10.1021/ja101557k Contact: Antonello Mai, University "La Sapienza", Rome, Italy e-mail: antonello.mai@uniroma1.it Contact: Andrea Mattevi, University of Pavia, Pavia, Italy e-mail: andrea.mattevi@unipv.it Contact: Saverio Minucci, European Institute of Oncology, Milan, Italy e-mail: saverio.minucci@ifom-ieo-campus.it
		SciBX 3(18); doi:10.1038/scibx.2010.549 Published online May 6, 2010		